Search research articles
Contact Us
Filters
Showing results (91-100 of 100) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 100 results.
Breast Cancer Research and Treatment
|
November 28, 2017
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
S L Villegas, S Darb-Esfahani, G von Minckwitz, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2013
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
Anne-Joy M de Graan, Laure Elens, Jason A Sprowl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
The Lancet. Child & Adolescent Health
|
September 29, 2022
Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, et al.
JACC. Cardiooncology
|
June 21, 2025
IGHG Recommendations for Anthracycline and Anthraquinone Cardiac Dysfunction Equivalence Ratios After Childhood Cancer: JACC: CardioOncology Expert Panel
Theodorus W Kouwenberg, Elvira C van Dalen, Renée L Mulder, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 100) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 100 results.
Breast Cancer Research and Treatment
|
November 28, 2017
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
S L Villegas, S Darb-Esfahani, G von Minckwitz, et al.
ESMO Open
|
November 28, 2025
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T Link, M Reinisch, M Just, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2016
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
S Loibl, C Jackisch, A Schneeweiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2013
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
Anne-Joy M de Graan, Laure Elens, Jason A Sprowl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P A Fasching, T Link, J Hauke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
The Lancet. Child & Adolescent Health
|
September 29, 2022
Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, et al.
JACC. Cardiooncology
|
June 21, 2025
IGHG Recommendations for Anthracycline and Anthraquinone Cardiac Dysfunction Equivalence Ratios After Childhood Cancer: JACC: CardioOncology Expert Panel
Theodorus W Kouwenberg, Elvira C van Dalen, Renée L Mulder, et al.
Page
of 10